| abstract |
FIELD: pharmacology. n SUBSTANCE: invention relates to a new pyridopyrimidine compound of general formula (Ia), a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compounds have AKT-mTOR (PI3K-AKT-mTOR) phosphatidylinositol-3-kinase kinase inhibitor properties and can be used to treat a disease or condition caused by dysfunction of the PI3K-AKT-mTOR signaling pathway, in particular a tumour disease. In the general formula (Ia), where each of R 1 and R 2 independently is 3-oxa-8-azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl or NR A R B , and at least one of R 1 and R 2 is 3-oxa-8-azabicyclo[3.2.1]octanyl or 8-oxa-3-azabicyclo[3.2.1]octanyl; and each of the R A and R B independently represents C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 alkoxy, or R A and R B together with N to which they are attached, form a morpholino ring which is unsubstituted or substituted C 1 -C 6 alkyl; and R 3 is , where Rc is C 1 -C 3 alkyl. n EFFECT: increased efficiency of compounds application. n 9 cl, 2 tbl, 52 ex |